Merck KGaA tries again on Erbitux for lung cancer

If at first you don't succeed, try again with a smaller patient group. That's the approach Merck KGaA is taking with Erbitux, after losing one bid to broaden use of the drug to lung cancer patients. In a new application for expanded use, Merck proposes Erbitux as a treatment for patients with a particular type of tumor, about one-fourth of the population it previously targeted.

As Reuters reports, Merck asked European regulators to consider Erbitux as a treatment for non-small cell lung cancers with high expression of epidermal growth factor receptor, or EGFR. Proper patients can be identified via a genetic test of their tumors. Erbitux is already approved to treat colorectal cancer and head and neck cancer.

The new application is based on a re-analysis of data in the lung cancer study Merck originally submitted to authorities. In sifting through that data, the company found that 44 percent of EGFR-positive patients treated with Erbitux had tumors that shrank over the study period. Only 28 percent of patients in the control group had tumor shrinkage, the news service reports.

- see the release from Merck KGaA
- read the Reuters news
- get more from InPharm

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.